Shares in cancer diagnostics company Pacific Edge have more than doubled in early trading on the NZX after the American Urological Association (AUA) included its Cxbladder triage as the standard of care, in a change to its clinical guideline for the management of patients presenting with
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
